![conference banner](/images/conference-banner.jpeg)
Abstract
Dopamine receptors have been identified in a number of organs and tissues, which include the central and peripheral nervous systems, various vascular beds, the heart, the gastrointestinal tract, and the kidney. Dopamine receptors are classified into D1- and D2-like subtypes based on their structure and pharmacology; during conditions of moderate sodium balance, more than 50% of renal sodium excretion is regulated by D1-like receptors. Most of the knowledge on the actions of dopamine has been focused on the D1 dopamine receptor. The D5 dopamine receptor also belongs to the D1-like receptor subfamily. Disruption of the D5 receptor results in hypertension. However, unlike the D1 receptor, the hypertension in D5 receptor null mice is caused by the increased activity of the sympathetic nervous system, apparently due to activation of oxytocin, V1 vasopressin, and non-NMDA receptors in the central nervous system. In this paper, we review the physiological action of D5 receptor on the central and peripheral nervous systems, and discuss the possible mechanisms by which hypertension develops when the D5 receptor function is perturbed.
Keywords: Essential hypertension, dopamine receptor, sympathetic nervous system, sodium excretion, vasorelaxation
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Regulation of Blood Pressure by D5 Dopamine Receptors
Volume: 5 Issue: 3
Author(s): Chunyu Zeng, Zhiwei Yang, Laureano D. Asico and Pedro A. Jose
Affiliation:
Keywords: Essential hypertension, dopamine receptor, sympathetic nervous system, sodium excretion, vasorelaxation
Abstract: Dopamine receptors have been identified in a number of organs and tissues, which include the central and peripheral nervous systems, various vascular beds, the heart, the gastrointestinal tract, and the kidney. Dopamine receptors are classified into D1- and D2-like subtypes based on their structure and pharmacology; during conditions of moderate sodium balance, more than 50% of renal sodium excretion is regulated by D1-like receptors. Most of the knowledge on the actions of dopamine has been focused on the D1 dopamine receptor. The D5 dopamine receptor also belongs to the D1-like receptor subfamily. Disruption of the D5 receptor results in hypertension. However, unlike the D1 receptor, the hypertension in D5 receptor null mice is caused by the increased activity of the sympathetic nervous system, apparently due to activation of oxytocin, V1 vasopressin, and non-NMDA receptors in the central nervous system. In this paper, we review the physiological action of D5 receptor on the central and peripheral nervous systems, and discuss the possible mechanisms by which hypertension develops when the D5 receptor function is perturbed.
Export Options
About this article
Cite this article as:
Chunyu Zeng , Zhiwei Yang , Laureano D. Asico and Pedro A. Jose , Regulation of Blood Pressure by D5 Dopamine Receptors, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (3) . https://dx.doi.org/10.2174/187152507781058708
DOI https://dx.doi.org/10.2174/187152507781058708 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Post Chikungunya Chronic Arthritis: Systemic Inflammatory Status Triggering Acute Coronary Syndrome
Current Rheumatology Reviews Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Heme Oxygenase System and Hypertension: A Comprehensive Insight
Current Pharmaceutical Design Synthesis of Dihydropyridines: Patented Catalysts and Biological Applications
Recent Patents on Catalysis (Discontinued) Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies
Current Drug Targets Survival Benefits of N-Acetylcysteine in Rodenticide Poisoning: Retrospective Evidence from an Indian Tertiary Care Setting
Current Reviews in Clinical and Experimental Pharmacology Editorial (Thematic Issue: Switching to Biological Agents in Autoimmune and Autoinflammatory Disorders: Current Targets and Therapy)
Current Medicinal Chemistry Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women
Current Vascular Pharmacology SGLT2 Inhibitors and Diabetic Kidney Disease: Targeting Multiple and Interrelated Signaling Pathways for Renal Protection
Current Molecular Pharmacology The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Guanabenz and Clonidine, α2-Adrenergic Receptor Agonists, Inhibit Choroidal Neovascularization
Current Neurovascular Research Aquaporin and Vascular Diseases
Current Neuropharmacology Anticoagulation in Patients with Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Hot Topic: Autosomal Dominant Polycystic Kidney Disease: Cardiovascular Complications)
Current Hypertension Reviews Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Current Evidence Regarding Low-carb Diets for The Metabolic Control of Type-2 Diabetes
Current Diabetes Reviews Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Endothelin-1 Impairs Retrograde Axonal Transport and Leads to Axonal Injury in Rat Optic Nerve
Current Neurovascular Research Transcription Factors as Molecular Targets: Molecular Mechanisms of Decoy ODN and their Design
Current Drug Targets The Woman’s Heart: Insights into New Potential Targeted Therapy
Current Medicinal Chemistry